CN113507928A - 用于治疗神经障碍的氘代占诺美林的化合物和方法 - Google Patents

用于治疗神经障碍的氘代占诺美林的化合物和方法 Download PDF

Info

Publication number
CN113507928A
CN113507928A CN202080014856.8A CN202080014856A CN113507928A CN 113507928 A CN113507928 A CN 113507928A CN 202080014856 A CN202080014856 A CN 202080014856A CN 113507928 A CN113507928 A CN 113507928A
Authority
CN
China
Prior art keywords
compound
medicament
formula
certain embodiments
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080014856.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·贝内特
G·阿塔尔多
C·施勒希特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Publication of CN113507928A publication Critical patent/CN113507928A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080014856.8A 2019-02-22 2020-02-21 用于治疗神经障碍的氘代占诺美林的化合物和方法 Pending CN113507928A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808954P 2019-02-22 2019-02-22
US62/808,954 2019-02-22
US201962936358P 2019-11-15 2019-11-15
US62/936,358 2019-11-15
PCT/US2020/019193 WO2020172516A1 (en) 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders

Publications (1)

Publication Number Publication Date
CN113507928A true CN113507928A (zh) 2021-10-15

Family

ID=72145029

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080014856.8A Pending CN113507928A (zh) 2019-02-22 2020-02-21 用于治疗神经障碍的氘代占诺美林的化合物和方法

Country Status (8)

Country Link
US (1) US20220144817A1 (https=)
EP (1) EP3927342A4 (https=)
JP (1) JP2022523355A (https=)
CN (1) CN113507928A (https=)
AU (1) AU2020226870A1 (https=)
BR (1) BR112021016457A2 (https=)
CA (1) CA3131128A1 (https=)
WO (1) WO2020172516A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119161338A (zh) * 2024-11-25 2024-12-20 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
US12269818B2 (en) * 2023-04-24 2025-04-08 Terran Biosciences Inc. Analogs of xanomeline
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777425A (zh) * 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂
US20170095465A1 (en) * 2009-07-22 2017-04-06 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US20170112820A1 (en) * 2009-07-22 2017-04-27 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508028A (ja) * 1994-10-31 1998-08-04 イーライ・リリー・アンド・カンパニー 不安を治療する方法
CA2239732A1 (en) * 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain
CA2754203A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777425A (zh) * 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂
US20170095465A1 (en) * 2009-07-22 2017-04-06 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US20170112820A1 (en) * 2009-07-22 2017-04-27 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王世真主编: "《分子核医学》", 31 March 2004, 中国协和医科大学出版社, pages: 417 - 418 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119161338A (zh) * 2024-11-25 2024-12-20 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用
CN119161338B (zh) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Also Published As

Publication number Publication date
JP2022523355A (ja) 2022-04-22
US20220144817A1 (en) 2022-05-12
CA3131128A1 (en) 2020-08-27
EP3927342A1 (en) 2021-12-29
AU2020226870A1 (en) 2021-09-09
EP3927342A4 (en) 2022-11-16
BR112021016457A2 (pt) 2021-10-13
WO2020172516A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
CN113507928A (zh) 用于治疗神经障碍的氘代占诺美林的化合物和方法
EP3810608B1 (en) Oga inhibitor compounds
CN106905322B (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
EP3372594B1 (en) Pyrimidine derivatives and their use for the treatment of cancer
EP3612519B1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
EP3544972B1 (en) Heteroarylphenoxy benzamide kappa opioid ligands
JPH05501540A (ja) Ｐｃｐレセプター・リガンドおよびその用途
CZ400892A3 (en) 2-(4-hydroxypiperidino)-1-alkanol derivatives as anti-ischemic agents, process of their preparation and use
US20250099596A1 (en) Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
CA3102584A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
CN115141149A (zh) 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
EP3233077B1 (en) Dopamine d2 receptor ligands
CN110357858B (zh) 具有穿过血脑屏障能力的5取代二氟哌啶化合物
EP0113587B1 (en) Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
EP2643307B1 (fr) Derives de nitrobenzothiazoles et leur utilisation pour le traitment de la tubercolose
JP2016500096A (ja) ナトリウム−ヨウ素シンポータの新規阻害剤
CA3160367A1 (en) Oga inhibitor compounds
US20040254196A1 (en) Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof
CN107501270A (zh) 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
EP2325169B1 (en) Lisofylline analogues and their pharmeacuetical uses
KR20100040881A (ko) 전구약물로서 벤라팍신 및 ｏ－데스메틸벤라팍신의 ｎ－옥사이드
EP3778589A1 (en) 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
CN114573591B (zh) 一种取代的吡咯并嘧啶化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211015